In Friday’s Wall Street session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares traded at $3.72, up 3.62% from the previous session.
AMLX stock price is now -4.53% away from the 50-day moving average and 18.41% away from the 200-day moving average. The market capitalization of the company currently stands at $255.01M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $3 to $11, Robert W. Baird Upgraded its rating from Neutral to Outperform for Amylyx Pharmaceuticals Inc (NASDAQ: AMLX). On October 23, 2024, BofA Securities Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock increasing its target price from $4.20 to quote $10, while ‘Mizuho’ rates the stock as ‘Neutral’
In other news, Mazzariello Gina, Chief Legal Officer sold 3,678 shares of the company’s stock on Feb 03 ’25. The stock was sold for $12,839 at an average price of $3.49. Upon completion of the transaction, the Chief Legal Officer now directly owns 139,090 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 03 ’25, Co-Chief Executive Officer Cohen Joshua B sold 11,851 shares of the business’s stock. A total of $41,108 was realized by selling the stock at an average price of $3.47. This leaves the insider owning 3,201,247 shares of the company worth $11.91 million. A total of 29.45% of the company’s stock is owned by insiders.
During the past 12 months, Amylyx Pharmaceuticals Inc has had a low of $1.58 and a high of $19.95. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 4.55, and a quick ratio of 4.55. The fifty day moving average price for AMLX is $3.8966 and a two-hundred day moving average price translates $3.1415 for the stock.
The latest earnings results from Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) was released for 2024-09-30. The net profit margin was -132.05% and return on equity was -84.43% for AMLX. The company reported revenue of $0.42 million for the quarter, compared to $102.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -99.59 percent.
